Noninvasive markers of fibrosis: Key concepts for improving accuracy in daily clinical practice

Annals of Hepatology

Volumn 11, Issue 4, 2012, Pages 426-439

  Duarte Rojo, Andrés ^a   Altamirano, José Trinidad ^b   Feld, Jordan J ^c  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b HOSPITAL CLÍNIC   (Spain)

^c TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

APRI; Fibrotest; Mortality; Transient elastography

Indexed keywords

ALPHA 2 MACROGLOBULIN; BILIRUBIN; BIOLOGICAL MARKER; CHOLESTEROL; GAMMA GLUTAMYLTRANSFERASE; HAPTOGLOBIN; HYALURONIC ACID; IMMUNOGLOBULIN; INTERFERON; RIBAVIRIN;

ACOUSTIC RADIATION FORCE IMPULSE IMAGING; ALCOHOL LIVER DISEASE; ALCOHOLIC FATTY LIVER; CLINICAL PRACTICE; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DISEASE COURSE; DISEASE MARKER; DISEASE SEVERITY; ELASTOGRAPHY; FATTY LIVER; HEALTH CARE COST; HEPATITIS; HEPATITIS B; HEPATITIS C; HISTOPATHOLOGY; HUMAN; LIVER BIOPSY; LIVER FIBROSIS; LONGITUDINAL STUDY; MAGNETIC RESONANCE ELASTOGRAPHY; MORTALITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PORTAL HYPERTENSION; PREDICTIVE VALUE; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; REFERENCE VALUE; RELIABILITY; REVIEW; RISK REDUCTION; SAMPLING ERROR; SCORING SYSTEM; STAGING; THROMBOCYTE COUNT; TRANSIENT ELASTOGRAPHY; TREATMENT RESPONSE; VALIDATION PROCESS; VIRAL CLEARANCE; BIOPSY; BLOOD; HOSPITALIZATION; LIVER; LIVER CIRRHOSIS; PATHOLOGY; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; TIME;

BIOLOGICAL MARKERS; BIOPSY; ELASTICITY IMAGING TECHNIQUES; HUMANS; LIVER; LIVER CIRRHOSIS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 84862011783     PISSN: 16652681     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1665-2681(19)31456-5     Document Type: Review

References (101)

1. Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD, American Association for the Study of Liver Diseases. Liver biopsy. Hepatology 2009; 49: 1017-44.
2. Goodman ZD. Grading and staging systems for inflamma tion and fibrosis in chronic liver diseases. J Hepatol 2007; 47: 598-607.
3. Cholongitas E, Senzolo M, Standish R, et al. A systematic review of the quality of liver biopsy specimens. AmJ Clin Pathol 2006; 125: 710-21.
4. Colloredo G, Guido M, Sonzogni A, Leandro G. Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease. J Hepatol 2003; 39: 239-44.
5. Garcia Tsao G, Friedman S, Iredale J, Pinzani M. Now there are many (stages) where before there was one: In search of a pathophysiological classification of cirrhosis. Hepatology 2010; 51: 1445-9.
6. Germani G, Hytiroglou P, Fotiadu A, Burroughs AK, Dhillon AP. Assessment of fibrosis and cirrhosis in liver biopsies: an update. Semin Liver Dis 2011; 31: 82-90.
7. Calès P, Oberti F, Michalak S, et al. A novel panel of blood markers to assess the degree of liver fibrosis. Hepatology 2005; 42: 1373-81.
8. Mallet V, Dhalluin Venier V, Roussin C, et al. The accuracy of the FIB 4 index for the diagnosis of mild fibrosis in chronic hepatitis B. Aliment Pharmacol Ther 2009; 29: 409-15.
9. Idobe Y, Murawaki Y, Ikuta Y, Koda M, Kawasaki H. Post prandial serum hyaluronan concentration in pa tients with chronic liver disease. Intern Med 1998; 37: 568-75.
10. Lin ZH, Xin YN, Dong QJ, et al. Performance of the aspar tate aminotransferase to platelet ratio index for the sta ging of hepatitis C related fibrosis: an updated meta analysis. Hepatology 2011; 53: 726-36.
11. Stibbe KJ, Verveer C, Francke J, et al. Comparison of non invasive assessment to diagnose liver fibrosis in chronic hepatitis B and C patients. Scand J Gastroenterol 2011; 46: 962-72.
12. Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006; 43: 1317-25.
13. Vallet Pichard A, Mallet V, Nalpas B, et al. FIB 4: an inex pensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and fibrotest. Hepatology 2007; 46: 32-6.
14. Kim BK, Kim DY, Park JY, et al. Validation of FIB 4 and comparison with other simple noninvasive indices for pre dicting liver fibrosis and cirrhosis in hepatitis B virus in fected patients. Liver Int 2010; 30: 546-53.
15. Koda M, Matunaga Y, Kawakami M, Kishimoto Y, Suou T, Murawaki Y. FibroIndex, a practical index for predicting significant fibrosis in patients with chronic hepatitis C. Hepatology 2007; 45: 297-306.
16. Forns X, Ampurdanès S, Llovet JM, et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 2002; 36: 986-92.
17. Siagris D, Christofidou M, Theocharis GJ, et al. Serum lipid pattern in chronic hepatitis C: histological and virological correlations. J Viral Hepat 2006; 13: 56-61.
18. Kim BK, Kim SA, Park YN, et al. Noninvasive models to pre dict liver cirrhosis in patients with chronic hepatitis B. Liver Int 2007; 27: 969-76.
19. Rosenberg WM, Voelker M, Thiel R, et al. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology 2004; 127: 1704-3.
20. Parkes J, Guha IN, Roderick P, et al. Enhanced Liver Fibro sis (ELF) test accurately identifies liver fibrosis in patients with chronic hepatitis C. J Viral Hepat 2011; 18: 23-31.
21. Kawser CA, Iredale JP, Winwood PJ, Arthur MJ. Rat hepatic stellate cell expression of alpha2 macroglobulin is a feature of cellular activation: implications for matrix remodelling in hepatic fibrosis. Clin Sci (Lond) 1998; 95: 179-86.
22. Patel K, Gordon SC, Jacobson I, et al. Evaluation of a panel of non invasive serum markers to differentiate mild from moderate to advanced liver fibrosis in chronic hepatitis C patients. J Hepatol 2004; 41: 935-42.
23. Patel K, Nelson DR, Rockey DC, et al. Correlation of FI BROSpect II with histologic and morphometric evaluation of liver fibrosis in chronic hepatitis C. Clin Gastroenterol Hepatol 2008; 6: 242-7.
24. Adams LA, Bulsara M, Rossi E, et al. Hepascore: an accura te validated predictor of liver fibrosis in chronic hepatitis C infection. Clin Chem 2005; 51: 1867-73.
25. Degos F, Perez P, Roche B, et al. Diagnostic accuracy of FibroScan and comparison to liver fibrosis biomarkers in chronic viral hepatitis: a multicenter prospective study (the FIBROSTIC study). J Hepatol 2010; 53: 1013-21.
26. Poynard T, de Ledinghen V, Zarski JP et al. FibroTest(®) and Fibroscan(®) performances revisited in patients with chronic hepatitis C. Impact of the spectrum effect and the applicability rate. Clin Res Hepatol Gastroenterol 2011 [epub ahead of print].
27. Halfon P, Munteanu M, Poynard T. FibroTest ActiTest as a non invasive marker of liver fibrosis. Gastroenterol Clin Biol 2008; 32: 22-39.
28. Leroy V, Halfon P, Bacq Y, et al. Diagnostic accuracy, re producibility and robustness of fibrosis blood tests in chronic hepatitis C: a meta analysis with individual data. Clin Biochem 2008; 41: 1368-76.
29. Poynard T, Ngo Y, Munteanu M, Thabut D, Ratziu V. Nonin vasive Markers of Hepatic Fibrosis in Chronic Hepatitis B. Curr Hepat Rep 2011; 10: 8797.
30. Guha IN, Myers RP, Patel K, Talwalkar JA. Biomarkers of li ver fibrosis: What lies beneath the receiver operating characteristic curve? Hepatology 2011; 54: 1454-62.
31. Zarski JP, Sturm N, Guechot J, et al. Comparison of nine blood tests and transient elastography for liver fibrosis in chronic hepatitis C: The ANRS HCEP 23 study. J Hepatol 2011 [epub ahead of print].
32. Bataller R, Rombouts K, Altamirano J, Marra F. Fibrosis in alcoholic and nonalcoholic steatohepatitis. Best Pract Res Clin Gastroenterol 2011; 25: 231-44.
33. Poynard T, Aubert A, Bedossa P, et al. A simple biological index for detection of alcoholic liver disease in drinkers. Gastroenterology 1991; 100: 1397-402.
34. Naveau S, Poynard T, Benattar C, Bedossa P, Chaput JC. Alpha 2 macroglobulin and hepatic fibrosis. Diagnostic in terest. Dig Dis Sci 1994; 39: 2426-32.
35. Naveau S, Gaudé G, Asnacios A, et al. Diagnostic and prog nostic values of noninvasive biomarkers of fibrosis in patients with alcoholic liver disease. Hepatology 2009; 49: 97-105.
36. Janssens F, de Suray N, Piessevaux H, Horsmans Y, de Ti mary P, Starkel P. Can transient elastography replace Liver histology for determination of advanced fibrosis in alcoholic patients: a real life study. J Clin Gastroenterol 2010; 44: 575-82.
37. Naveau S, Raynard B, Ratziu V, et al. Biomarkers for the prediction of liver fibrosis in patients with chronic alcoholic liver disease. Clin Gastroenterol Hepatol 2005; 3: 167-74.
38. Lavallard VJ, Bonnafous S, Patouraux S, et al. Serum mar kers of hepatocyte death and apoptosis are non invasive biornarkers of severe fibrosis in patients with alcoholic liver disease. PLoS One 2011; 6: 17599.
39. Angulo P, Hui JM, Marchesini G, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007; 45: 846-54.
40. Harrison SA, Oliver D, Arnold HL, Gogia S, Neuschwander Tetri BA. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut 2008; 57: 1441-7.
41. Ratziu V, Massard J, Charlotte F, et al. Diagnostic value of biochemical markers (FibroTest FibroSURE) for the prediction of liver fibrosis in patients with non alcoholic fatty Liver disease. BMC Gastroenterol 2006; 6: 6.
42. Calès P, Lainé F, Boursier J, et al. Comparison of blood tests for liver fibrosis specific or not to NAFLD. J Hepatol 2009; 50: 165-73.
43. Guha IN, Parkes J, Roderick P, et al. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology 2008; 47: 455-60.
44. Shah AG, Lydecker A, Murray K, et al. Comparison of non invasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2009; 7: 1104-12.
45. Adams LA, George J, Bugianesi E, et al. Complex non invasive fibrosis models are more accurate than simple models in non alcoholic fatty liver disease. J Gastroenterol Hepatol 2011; 26: 1536-43.
46. Loaeza del Castillo A, Paz Pineda F, Oviedo Cardenas E, et al. AST to platelet ratio index (APRI) for the noninva sive evaluation of liver fibrosis. Ann Hepatol 2008; 7: 350-7.
47. Floreani A, Cazzagon N, Martines D, Cavalletto L, Baldo V, Chemello L. Performance and utility of transient elastography and noninvasive markers of liver fibrosis in primary biliary cirrhosis. Dig Liver Dis 2011; 43: 887-92.
48. Friedrich Rust M, Muller C, Winckler A, et al. Assessment of liver fibrosis and steatosis in PBC with FibroScan, MRI, MR spectroscopy, and serum markers. J Clin Gastroente rol 2010; 44: 58-65.
49. Castera L, Forns X, Alberti A. Non invasive evaluation of liver fibrosis using transient elastography. J Hepatol 2008; 48: 835-47.
50. Fraquelli M, Rigarnonti C, Casazza G, et al. Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease. Gut 2007; 56: 968-73.
51. Lucidarme D, Foucher J, Le Bail B, et al. Factors of accuracy of transient elastography (fibroscan) for the diagnosis of liver fibrosis in chronic hepatitis C. Hepatology 2009; 49: 1083-9.
52. Castéra L, Foucher J, Bernard PH, et al. Pitfalls of liver stiffness measurement: a 5 year prospective study of 13,369 examinations. Hepatology 2010; 51: 828-35.
53. Myers RP, Pornier Layrargues G, Kirsch R, et al. Feasibility and diagnostic performance of the fibroscan xl probe for liver stiffness measurement in overweight and obese patients. Hepatology 2012; 54: 199-208.
54. Myers RP, Pomier Layrargues G, Kirsch R, et al. Discordance in fibrosis staging between liver biopsy and transient elastography using the fibroscan XL probe. J Hepatol 2012 [epub ahead of print].
55. Tsochatzis EA, Gurusamy KS, Ntaoula S, Cholongitas E, Da vidson BR, Burroughs AK. Elastography for the diagnosis of severity of fibrosis in chronic liver disease: a meta analysis of diagnostic accuracy. J Hepatol 2011; 54: 650-9.
56. Castéra L, Vergniol J, Foucher J, et al. Prospective corn parison of transient elastography, fibrotest, APRI, and liver biopsy for the assessrnent of fibrosis in chronic hepatitis C. Gastroenterol 2005; 128: 343-50.
57. Ziol M, Handra Luca A, Kettaneh A, et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology 2005; 41: 48-54.
58. Marcellin P, Ziol M, Bedossa P, et al. Non invasive assessment of liver fibrosis by stiffness measurement in patients with chronic hepatitis B. Liver Int 2009; 29: 242-7.
59. Coco B, Oliveri F, Maina AM, et al. Transient elastography: a new surrogate marker of liver fibrosis influenced by major changes of transaminases. J Viral Hepat 2007; 14: 360-9.
60. Arena U, Vizzutti F, Corti G, et al. Acute viral hepatitis in creases liver stiffness values measured by transient elastography. Hepatology 2008; 47: 380-4.
61. Kim SU, Kim do Y, Park JY, et al. How can we enhance the performance of liver stiffness measurement using FibroScan in diagnosing liver cirrhosis in patients with chronic hepatitis B? JClin Gastroenterol 2010; 44: 66-71.
62. Chap HL, Wong GL, Choi PC, et al. Alanine aminotransferase based algorithms of liver stiffness measurement by transient elastography (Fibroscan) for liver fibrosis in chronic hepatitis B. J Viral Hepat 2009; 16: 36-44.
63. Lupsor M, Badea R, Stefänescu H, et al. Analysis of histopathological changes that influence liver stiffness in chronic hepatitis C. Results from a cohort of 324 patients. J Gastrointestin Liver Dis 2008; 17: 155-63.
64. Wong VW, Vergniol J, Wong GL, et al. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology; 2010 51: 454-62.
65. Nguyen Khac E, Chatelain D, Tramier B, et al. Assessment of asymptomatic liver fibrosis in alcoholic patients using fibros can: prospective comparison with seven non invasive laboratory tests. Aliment Pharmacol Ther 2008; 28: 1188-98.
66. Nahon P, Kettaneh A, Tengher Barna I, et al. Assessment of liver fibrosis using transient elastography in patients with alcoholic liver disease. J Hepatol 2008; 49: 1062-8.
67. Yoneda M, Mawatari H, Fujita K, et al. Noninvasive assesment of liver fibrosis by measurement of stiffness in pa tients with nonalcoholic fatty liver disease (NAFLD). Dig Liver Dis 2008; 40: 371-8.
68. Mueller S, Millonig G, Sarovska L, et al. Increased liver stiffness in alcoholic liver disease: differentiating fibrosis from steatohepatitis. World J Gastroenterol 2010; 16: 966-72.
69. Corpechot C, El Naggar A, Poujol Robert A, et al. Assessment of biliary fibrosis by transient elastography in patients with PBC and PSC. Hepatology 2006; 43: 1118-24.
70. Yin M, Talwalkar JA, Glaser KJ, et al. Assessment of hepatic fibrosis with magnetic resonance elastography. Clin Gastroenterol Hepatol 2007; 5: 1207-13.
71. Huwart L, Sempoux C, Vicaut E, et al. Magnetic resonance elastography for the noninvasive staging of liver fibrosis. Gastroenterology 2008; 135: 3240.
72. Wang Y, Ganger DR, Levitsky J, et al. Assessment of chronic hepatitis and fibrosis: comparison of MR elastography and diffusion weighted imaging. AJR Am J Roentgenol 2011; 196: 553-61.
73. Friedrich Rust M, Romen D, Vermehren J, et al. Acoustic radiation force impulse imaging and transient elastography for non invasive assessment of liver fibrosis and stea tosis in NAFLD. Eur J Radiol 2011 [in press].
74. Friedrich Rust M, Wunder K, Friener S, et al. Liver fibrosis in viral hepatitis: noninvasive assessment with acoustic radiation force impulse imaging versus transient elastography. Radiology 2009; 252: 595-604.
75. Ebinuma H, Saito H, Komuta M, et al. Evaluation of liver fibrosis by transient elastography using acoustic radiation force impulse: comparison with Fibroscan(®). J Gastroenterol 2011; 46: 1238-48.
76. Palmeri ML, Wang MH, Rouze NC, et al. Noninvasive evaluation of hepatic fibrosis using acoustic radiation force based shear stiffness in patients with nonalcoholic fatty liver disease. J Hepatol 2011; 55: 666-72.
77. Rizzo L, Calvaruso V, Cacopardo B, et al. Comparison of transient elastography and acoustic radiation force impulse for non invasive staging of liver fibrosis in patients with chronic hepatitis c. AmJ Gastroenterol 2011; 106: 2112-20.
78. Bourlière M, Pénaranda G, Adhoute X, Oules V, Castellani P. Combining non invasive methods for assessment of liver fibrosis. Gastroenterol Clin Biol 2008; 32: 73-9.
79. Castéra L, Sebastiani G, Le Bail B, de Lédinghen V, Couzigou P, Alberti A. Prospective comparison of two algorithms combining non invasive methods for staging liver fibrosis in chronic hepatitis C. J Hepatol 2010; 52: 191-8.
80. Boursier J, de Ledinghen V, Zarski J P, et al. Comparison of eight diagnostic algorithms for liver fibrosis in hepatitis C: new algorithms are more precise and entirely noninvasive. Hepatology 2011; 55: 58-67.
81. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2011s; 55: 245-64.
82. Poynard T, Imbert Bismut F, Ratziu V, et al. Biochemical markers of liver fibrosis in patients infected by hepatitis C virus: longitudinal validation in a randomized trial. J Viral Hepat 2002; 9: 128-33.
83. Patel K, Benhamou Y. Yoshida EM, et al. An independent and prospective comparison of two commercial fibrosis marker panels (HCV FibroSURE and FIBROSpect II) during albinterferon alfa 2b combination therapy for chronic hepatitis C. J Viral Hepat 2009; 16: 178-86.
84. Vergniol J, Foucher J, Castéra L, et al. Changes of non invasive markers and FibroScan values during HCV treatment. J Viral Hepat 2009; 16: 132-40.
85. Martinez SM, Fernández Varo G, Gonzalez P, et al. Assessment of liver fibrosis before and after antiviral the rapy by different serum marker panels in patients with chronic hepatitis C. Aliment Pharmacol Ther 2011; 33: 138-48.
86. 3 program. J Hepatol 2011; 54: 227-35.
87. Hézode C, Castéra L, Roudot Thoraval F, et al. Liver stiffness diminishes with antiviral response in chronic hepatitis C. Aliment Pharmacol Ther 2011; 34: 656-63.
88. Ogawa E, Furusyo N, Toyoda K, Takeoka H, Maeda S, Hayashi J. The longitudinal quantitative assessment by transient elastography of chronic hepatitis C patients treated with pegylated interferon alpha 2b and ribavirin. Antiviral Res 2009; 83: 127-34.
89. van der Meer, Veldt BJ, Feld JJ, et al. Improved platelet count and smaller spleen size long after sustained virologi cal response in chronic hepatitis c patients with advanced fibrosis. Hepatology 2011; 54(Suppl.): 820A.
90. Enomoto M, Mori M, Ogawa T, et al. Usefulness of tran sient elastography for assessment of liver fibrosis in chronic hepatitis B: Regression of liver stiffness during entecavir therapy. Hepatol Res 2010; 40: 853-61.
91. Bureau C, Metivier S, Peron JM, et al. Transient elastography accurately predicts presence of significant portal hypertension in patients with chronic liver disease. Aliment Pharmacol Ther 2008: 27: 1261-8.
92. Robic MA, Procopet B, Métivier S, et al. Liver stiffness accurately predicts portal hypertension related complications in patients with chronic liver disease: A prospective study. J Hepatol 2011; 55: 1017-25.
93. Hirooka M, Ochi H, Koizumi Y, et al. Splenic elasticity mea sured with real time tissue elastography is a marker of portal hypertension. Radiology 2011; 261: 960-8.
94. Talwalkar JA, Yin M, Venkatesh S, et al. Feasibility of in vivo MR elastographic splenic stiffness measurements in the assessment of portal hypertension. AJR Am J Roentgenol 2009; 193: 122-7.
95. Stefanescu H, Grigorescu M, Lupsor M, Procopet B, Maniu A, Badea R. Spleen stiffness measurement using fibroscan for the noninvasive assessment of esophageal varices in liver cirrhosis patients. J Gastroenterol Hepatol 2011; 26: 164-70.
96. Fung J, Lai CL, Seto WK, Wong DK, Yuen MF. Prognostic significance of liver stiffness for hepatocellular carcinoma and mortality in HBeAg negative chronic hepatitis B. J Viral Hepat 2011; 18: 738-44.
97. Thabut D, Imbert Bismut F, Cazals Hatem D, et al. Relationship between the Fibrotest and portal hypertension in patients with liver disease. Aliment Pharmacol Ther 2007; 26: 359-68.
98. Ngo Y, Munteanu M, Messous D, et al. A prospective analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis C. Clin Chem 2006; 52: 1887-96.
99. Ngo Y, Benhamou Y, Thibault V, et al. An accurate definition of the status of inactive hepatitis B virus carrier by a combination of biomarkers (FibroTest ActiTest) and viral load. PLoS One 2008; 3: 2573.
100. Mayo MJ, Parkes J, Adams Huet B, et al. Prediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis assay. Hepatology 2008; 48: 1549-57.
101. Vergniol J, Foucher J, Terrebonne E, et al. Noninvasive tests for fibrosis and liver stiffness predict 5 year outcomes of patients with chronic hepatitis C. Gastroenterology 2011; 140: 1970-9.